Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease

Cushing's Disease Clinical Trial

— LINC-4  

Official title:

A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02697734
• Other study ID #: CLCI699C2302
• Status: Completed
• Phase: Phase 3
• Start date: October 3, 2016
• Est. completion date: December 31, 2020

Study information

• Verified date: October 2021
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.

Description:

The study LCI699C2302 (LINC-4) is a multi-center, randomized, double-blind study to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease.

Enrolled patients were initially randomized to either osilodrostat or placebo, in a 2:1 ratio, for a 12-week double-blind period (Period 1). Randomization was stratified by history of pituitary radiation. After Week 12, all patients received open-label osilodrostat until the end of the Core phase at Week 48 (Period 2).

After Week 48, patients could join an optional 48 week extension period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: December 31, 2020
• Est. primary completion date: June 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Key inclusion criteria:

• Confirmed Cushing's Disease (CD) that is persistent or recurrent as evidenced by all of the following criteria being met (i.e., a, b and c):

1. mUFC > 1.3 x ULN (Mean of three 24-hour urine samples collected preferably on 3 consecutive days, during screening after washout of prior medical therapy for CD (if applicable), confirmed by the central laboratory and available before Day 1), with =2 of the individual UFC values being > 1.3 x ULN.

2. Morning plasma Adrenocorticotropic hormone (ACTH) above Lower Limit of Normal

3. Confirmation (based on medical history) of pituitary source of excess

ACTH as defined by any one or more of the following three criteria:

i. Histopathologic confirmation of an ACTH-staining adenoma in patients who have had prior pituitary surgery. OR ii. Magnetic resonance imaging (MRI) confirmation of pituitary adenoma > 6 mm OR iii. Bilateral inferior petrosal sinus sampling (BIPSS) with either corticotropic-releasing hormone (CRH) or desmopressin (DDAVP) stimulation for patients with a tumor = 6mm. The criteria for a confirmatory BIPSS test are any of the following: Pre-dose central to peripheral ACTH gradient > 2; Post-dose central to peripheral ACTH gradient > 3 after either CRH or DDAVP stimulation

• Patients that received glucocorticoid replacement therapy must have discontinued such therapy for at least seven days or 5 half-lives prior to screening, whichever is longer.

• Patients with de novo CD can be included only if they are not considered candidates for surgery (e.g., poor surgical candidates due to co-morbidities, inoperable tumors, patients who refuse to have surgical treatment, or surgical treatment is not available).

Key exclusion criteria:

• Patients with pseudo-Cushing's syndrome. This may be diagnosed by a normal late night salivary cortisol value collected during the screening period and after washout of prior CD medication.

• Patients with risk factors for QT corrected (QTc) prolongation or Torsade de Pointes, including:

patients with a baseline QT corrected (Fridericia QT formula) (QTcF) > 450 ms for males and QTcF > 460 ms for females; personal or family history of long QT syndrome; concomitant medications known to prolong the QT interval; patients with hypokalemia, hypocalcaemia, or hypomagnesaemia, if not corrected before pre-dose Day 1.

• Patients likely to require adrenalectomy, pituitary surgery, or radiation therapy during the placebo-controlled period (Weeks 1-12) for the treatment of severe hypercortisolism or pituitary tumor growth causing compression of the optic chiasm.

• Patients with compression of the optic chiasm due to a macroadenoma or patients at high risk of compression of the optic chiasm (tumor within 2 mm of optic chiasm).

• Patients who have a known inherited syndrome as the cause for hormone over secretion (i.e. Carney Complex, McCune-Albright syndrome, MEN-1, AIP).

• Patients with Cushing's syndrome due to ectopic ACTH secretion or ACTH independent (adrenal) Cushing's syndrome. Pregnant or nursing (lactating) women. 8. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after completion of dosing. Highly effective contraception methods include: A. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. B. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study drug. In case of bilateral oophorectomy, documentation is required (e.g. operative report, pelvic ultrasound or other reliable imaging method). C. Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.

D. Combination of any two of the following (a+b or a+c, or b+c):

1. Use of oral*, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception

2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)

3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository. *In the case of use of oral contraception, women should have been stable on the same pill for a minimum of 3 months before taking study drug. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential.

Related Conditions & MeSH terms

• ACTH-Secreting Pituitary Adenoma
• Cushing's Disease
• Pituitary ACTH Hypersecretion

Intervention

Drug:
• osilodrostat
In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
• osilodrostat Placebo
Matching Placebo in the form of filmcoated tablets for oral administration

Locations

Country	Name	City	State
Belgium	Novartis Investigative Site	Leuven
Brazil	Novartis Investigative Site	Fortaleza	CE
Brazil	Novartis Investigative Site	Rio de Janeiro	RJ
Brazil	Novartis Investigative Site	Sao Paulo	SP
Brazil	Novartis Investigative Site	Sao Paulo	SP
Canada	Novartis Investigative Site	Halifax	Nova Scotia
Canada	Novartis Investigative Site	Montreal	Quebec
Canada	Novartis Investigative Site	Sherbrooke	Quebec
China	Novartis Investigative Site	Beijing
China	Novartis Investigative Site	Beijing
China	Novartis Investigative Site	Chengdu	Sichuan
China	Novartis Investigative Site	Guang Zhou
Costa Rica	Novartis Investigative Site	San Pedro	San Jose, Costa Rica
Greece	Novartis Investigative Site	Athens
Poland	Novartis Investigative Site	Krakow
Poland	Novartis Investigative Site	Warszawa
Poland	Novartis Investigative Site	Warszawa	Mazowieckie
Portugal	Novartis Investigative Site	Porto
Russian Federation	Novartis Investigative Site	Moscow
Spain	Novartis Investigative Site	Alzira	Comunidad Valenciana
Spain	Novartis Investigative Site	La Coruna	Galicia
Spain	Novartis Investigative Site	Madrid
Spain	Novartis Investigative Site	Malaga	Andalucia
Spain	Novartis Investigative Site	Sevilla	Andalucia
Spain	Novartis Investigative Site	Valencia	Comunidad Valenciana
Switzerland	Novartis Investigative Site	Luzern
Thailand	Novartis Investigative Site	Bangkok	THA
Thailand	Novartis Investigative Site	Bangkok
Turkey	Novartis Investigative Site	Istanbul
Turkey	Novartis Investigative Site	Kocaeli
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	University of Colorado Endocrinology Clinical Trials Unit	Aurora	Colorado
United States	Columbia University Medical Center New York Presbyterian Neuroendocrine Unit	New York	New York
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	University of Pennsylvania Medical Center University of Pennsylvania	Philadelphia	Pennsylvania
United States	Oregon Health and Science University SC LCI699C2301	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Belgium,  Brazil,  Canada,  China,  Costa Rica,  Greece,  Poland,  Portugal,  Russian Federation,  Spain,  Switzerland,  Thailand,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Randomized Participants With a Complete Response	A complete responder at week 12 is defined as a participant who had a mean urine free cortisol = upper limit of normal (mUFC = ULN) at Week 12.; Participants who had a missing mUFC assessment at Week 12 were counted as non-responders for the primary endpoint.	at Week 12
Secondary	Percentage of Participants With mUFC = ULN at Week 36	The complete response rate in both arms combined at Week 36. A complete responder at Week 36 is defined as a participant who had mean urine free cortisol <= upper limit of normal (mUFC <= ULN) at Week 36. Participants with missing mUFC at Week 36 were counted as non-responders.	At Week 36
Secondary	Change From Baseline in mUFC	To assess the change in mean urinary free cortisol (mUFC) from baseline by treatment arm.	Baseline, weeks 2,5,8,12,14,17,20,23,26,29,32,36,40,48,60,72,84,96
Secondary	Time-to-first Control of mUFC - Number (%) of Participants With mUFC <=ULN	To assess time-to-first control of mUFC, (in days) from randomization to the first mUFC collection that was = ULN before completion/discontinuation of placebo-controlled period.; Participants who did not achieve post-baseline mUFC control were censored at discontinuation or completion of placebo-controlled period, whichever was earlier.	up to 12 weeks
Secondary	Time-to-first Control of mUFC - Median Time to First Controlled mUFC Response	To assess time-to-first control of mUFC, (in days) from randomization to the first mUFC collection that was = ULN before completion/discontinuation of placebo-controlled period.; Participants who did not achieve post-baseline mUFC control were censored at discontinuation or completion of placebo-controlled period, whichever was earlier.; The median time-to-first control and corresponding two-sided 95% Confidence Interval were calculated using Kaplan-Meier methodology of Brookmeyer and Crowley (1982).	up to 12 weeks
Secondary	Time-to-first Control of mUFC - % Event Probability Estimates	To assess time-to-first control of mUFC, (in days) from randomization to the first mUFC collection that was = ULN before completion/discontinuation of placebo-controlled period.; Participants who did not achieve post-baseline mUFC control were censored at discontinuation or completion of placebo-controlled period, whichever was earlier.; % Event probability estimate is the estimated probability that a participant will have an event prior to the specified time point. % Event probability estimates are obtained from the Kaplan-Meier survival estimates for all treatment groups; Greenwood formula is used for Confidence Interval (CI) of Kaplan-Meier (KM) estimates.	up to 12 weeks
Secondary	Time-to-escape During Osilodrostat Treatment From Collection of Normal mUFC (= ULN) to the First mUFC > 1.3 x ULN - Number (%) of Participants	To assess time-to-escape from the first collection of normal mUFC (= ULN) to the first mUFC > 1.3 x ULN on two consecutive visits on the highest tolerated dose of osilodrostat and not related to a dose interruption or dose reduction due to safety reasons. Escape will not be assessed for participants during the first 26 weeks.	up to 48 weeks
Secondary	Time-to-escape During Osilodrostat Treatment From Collection of Normal mUFC (= ULN) to the First mUFC > 1.3 x ULN - Median Time to Escape From Normal mUFC	To assess time-to-escape from the first collection of normal mUFC (= ULN) to the first mUFC > 1.3 x ULN on two consecutive visits on the highest tolerated dose of osilodrostat and not related to a dose interruption or dose reduction due to safety reasons. Escape will not be assessed for participants during the first 26 weeks.; The median time-to-escape and corresponding two-sided 95% Confidence Interval were calculated using Kaplan-Meier methodology of Brookmeyer and Crowley (1982).	from week 26 to week 48
Secondary	Time-to-escape During Osilodrostat Treatment From Collection of Normal mUFC (= ULN) to the First mUFC > 1.3 x ULN - % Event Probability Estimates	Escape is defined as the first loss of control of urinary free cortisol (UFC) that meets all of the following criteria: 1. prior normalization of UFC has occurred (median urinary free cortisol (mUFC)= upper limit of normal (ULN)); 2. patient reached the highest tolerated dose of osilodrostat; 3. 2 consecutive mUFC (collected at scheduled visits) were above 1.3x ULN; 4. the loss of control of UFC is not related to a dose interruption or dose reduction due to safety reasons; 5. happened beyond Week 26 when the patients have a chance to be treated with doses as high as 30 mg bid.; Event probability estimate is the estimated probability that a participant will have an event prior to the specified time point.; Event probability estimates are obtained from the Kaplan-Meier survival estimates for all treatment groups; Greenwood formula is used for CI of KM estimates.	week 26 and week 36
Secondary	Change From Baseline in Bone Mineral Density (BMD) by Dual-energy X-ray Absorptiometry (DXA) Scan at the Femoral Neck, Hip and Spinal Cord - QC Corrected	The change from baseline in bone mineral density at the femoral neck, hip and spinal cord at Week 48 by treatment arm - QC corrected. An increase in bone mineral density is indicative of an improvement.	Baseline, week 48
Secondary	Change From Baseline in Bone Mineral Density (BMD) T-score by Dual-energy X-ray Absorptiometry (DXA) Scan at the Femoral Neck, Hip and Spinal Cord - QC Corrected	The change from baseline in bone mineral density at the femoral neck, hip and spinal cord at Week 48 by treatment arm - QC corrected. An increase in bone mineral density is indicative of an improvement. T-score is the number of standard deviations above or below the mean for a healthy 30-year-old adult of the same sex and ethnicity as the patient. The WHO criteria are: Normal is a T-score of -1.0 or higher"	Baseline, week 48
Secondary	Patients With a Complete Response (mUFC = ULN) or a Partial Response (mUFC Decrease = 50% From Baseline and >ULN) at Week 12, 36 and 48	Overall response rate defined as percentage of complete responders (mUFC = ULN) plus partial responders (= 50% reduction in mUFC from baseline and >ULN) at week 12, 36, 48 by treatment arms for all patients.	baseline, week 12, 36 and 48
Secondary	Change in Fasting Plasma Glucose	Change from baseline in fasting plasma glucose at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Hemoglobin A1C	Change from baseline in Hemoglobin A1C (%) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Cholesterol	Change from baseline in Cholesterol (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in LDL Cholesterol	Change from baseline in LDL Cholesterol (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in HDL Cholesterol	Change from baseline in HDL Cholesterol (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Triglyceride	Change from baseline in Triglyceride (mmol/L) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Standing Systolic Blood Pressure	Change from baseline in Standing Systolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Supine Systolic Blood Pressure	Change from baseline in Supine Systolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Standing Diastolic Blood Pressure	Change from baseline in Standing Diastolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Supine Diastolic Blood Pressure	Change from baseline in Supine Diastolic Blood Pressure (mmHg) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Weight	Change from baseline in Weight (kg) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change in Waist Circumference	Change from baseline in Waist Circumference (cm) at Week 12, Week 36, and Week 48 by treatment arm	Baseline, weeks 12, 36, and 48
Secondary	Change From Baseline to Week 12, Week 36, and Week 48 in Clinical Signs of Cushing's Disease	Change from baseline to Week 12, Week 36, and Week 48 in each of the following clinical signs of Cushing's disease, captured by: a semi-quantitative Likert scale for facial rubor, striae, supraclavicular fat pad, dorsal fat pad, proximal muscle wasting (atrophy), central (abdominal) obesity, and ecchymoses (bruises) by randomized treatment arm. The number/proportion of participants with an improvement or no change compared to baseline are reported	baseline, Week 12, Week 36 and Week 48
Secondary	Change From Baseline in Standardized Health Related Quality of Life Score, Using Cushing Disease-specific Quality of Life Patient Reported Outcome (PRO) Assessment	The CushingQoL is a valid and reliable disease-specific QoL questionnaire which assesses health-related quality of life (HRQoL) in patients with Cushing's syndrome and has been validated in patients with Cushing's disease. The CushingQoL consists of questions reflecting dimensions of HRQoL related to physical aspects (e.g. 'I bruise easily'), psychological aspects (e.g. 'I am more irritable, I have sudden mood swings and angry outbursts'), and social aspects (e.g. 'I have had to give up my social or leisure activities due to my illness').; The questionnaire consists of 12 items measured on a five point Likert-type scale assessing how often or how much each item has been related to the patient's Cushing's disease in the previous week. The raw score is calculated by summing the individual item scores prior to being standardized so that the total score ranges from 0 to 100. Increases from baseline are indicative of an improvement.	Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48.
Secondary	Change From Baseline in Standardized Psychosocial Issues Score, Using Cushing Disease-specific Quality of Life Patient Reported Outcome (PRO) Assessment	The CushingQoL is a valid and reliable disease-specific QoL questionnaire which assesses health-related quality of life (HRQoL) in patients with Cushing's syndrome and has been validated in patients with Cushing's disease. The CushingQoL consists of questions reflecting dimensions of HRQoL related to physical aspects (e.g. 'I bruise easily'), psychological aspects (e.g. 'I am more irritable, I have sudden mood swings and angry outbursts'), and social aspects (e.g. 'I have had to give up my social or leisure activities due to my illness').; The questionnaire consists of 12 items measured on a five point Likert-type scale assessing how often or how much each item has been related to the patient's Cushing's disease in the previous week. The raw score is calculated by summing the individual item scores prior to being standardized so that the total score ranges from 0 to 100. Increases from baseline are indicative of an improvement.	Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48.
Secondary	Change From Baseline in Standardized Physical Problems Score, Using Cushing Disease-specific Quality of Life Patient Reported Outcome (PRO) Assessment	The CushingQoL is a valid and reliable disease-specific QoL questionnaire which assesses health-related quality of life (HRQoL) in patients with Cushing's syndrome and has been validated in patients with Cushing's disease. The CushingQoL consists of questions reflecting dimensions of HRQoL related to physical aspects (e.g. 'I bruise easily'), psychological aspects (e.g. 'I am more irritable, I have sudden mood swings and angry outbursts'), and social aspects (e.g. 'I have had to give up my social or leisure activities due to my illness').; The questionnaire consists of 12 items measured on a five point Likert-type scale assessing how often or how much each item has been related to the patient's Cushing's disease in the previous week. The raw score is calculated by summing the individual item scores prior to being standardized so that the total score ranges from 0 to 100. Increases from baseline are indicative of an improvement.	Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48.
Secondary	Change From Baseline in EQ-5D-5L Utility Index	EQ-5D-5L Utility Index: The EQ-5D-5L questionnaire is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L measures 5 items on mobility, self-care, usual activities, pain/discomfort, anxiety/depression, measured on 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. A utility index can be computed from the EQ 5D-5L descriptive system with utility scores ranging from -0.281 (worst imaginable health state) to 1 (best imaginable health state), with -0.281 representing an "unconscious" health state. A single index value is analyzed for the EQ-5D-5L score. An increase from baseline in the EQ-ED-5L utility index is indicative of an improvement.	Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48.
Secondary	Change From Baseline in EQ-5D VAS	The EQ-5D-5L also includes a 20 cm vertical, VAS (visual analogue scale) with a scale of 0-100, with endpoints labeled 100='the best health you can imagine' and 0='the worst health you can imagine'. A single index value is analyzed for the EQ-5D-5L VAS score. An increase from baseline in the EQ-ED-5L VAS is indicative of an improvement.	Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48.
Secondary	Change From Baseline in Beck Depression Inventory-II - Total Score Derived	The Beck Depression Inventory II (BDI-II) is a patient reported instrument that consists of 21 items designed to assess the intensity of depression in clinical and normal patients in the preceding two weeks. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. A global score ranges from 0 to 63 and is calculated with a higher score representing a greater level of depression. The following scoring guidelines for interpretation of BDI-II have been suggested (Smarr, 2011): Minimal range =0-13, Mild depression =14-19, Moderate depression =20-28 and Severe depression = 29-63. A reduction from baseline in BDI-II is indicative of an improvement.	Baseline to Week 12 and 48, Week 12 to Week 36, Week 36 to Week 48.
Secondary	Change From Baseline in Serum Cortisol	Change from baseline in serum cortisol	Baseline, Week 12, Week 36, Week 48
Secondary	Change From Baseline in Late Night Saliva Cortisol	Change from baseline in late night saliva cortisol (nmol/L)	Baseline, Week 12, Week 36, Week 48
Secondary	Change From Baseline in Morning Saliva Cortisol	Change from baseline in morning saliva cortisol (nmol/L)	Baseline, Week 12, Week 36, Week 48
Secondary	Change From Baseline in Hair Cortisol Levels	Change from baseline in hair cortisol levels	Baseline, Week 26, Week 48
Secondary	Plasma Osilodrostat Concentrations (ng/mL)	Plasma osilodrostat concentrations (ng/mL)	pre-dose and 1-2hrs post dose at weeks 1, 2, 5, 8, 12, 14, 20, 26